The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Immunovant, Inc(NASDAQ:IMVT) 
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phas...
Share this website to your friends
Immunovant Days Payable Outstanding ttm (DPO)
Immunovant Days Inventory Outstanding ttm (DIO)
Immunovant Op Cashflow Per Share ttm
Immunovant Free Cashflow Per Share ttm
Immunovant Cash Per Share ttm
Immunovant (GAAP) P/E ratio ttm
Immunovant P/B ratio ttm
No extra charts and metrics for this ticker.